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1. Introduction 
Although rare, testicular cancer is the most common solid tumor in men between ages 20 
and 34, with approximately 5.5 new cases per 100,000 men reported in the United States 
each year (Howlader et al., 2011). For reasons that are still unclear, the incidence of testicular 
cancer worldwide has doubled in the past 40 years, with the most significant increases seen 
in industrialized countries in North America, Europe and Oceania (Huyghe et al., 2003). The 
vast majority of malignant testicular tumors are testicular germ cell tumors (TGCTs), which 
can be divided into two main categories: seminomas and non-seminomas. The pathogenesis 
of TGCTs has been the subject of intense interest recently due to the rising incidence (Chia et 
al., 2010). Skakkebaek was the first to describe the possibility of a pre-invasive lesion for 
testicular cancer in 1972, when he identified atypical germ cells in the testes of two infertile 
men who later developed TGCTs (Skakkebaek, 1972). Subsequent work by Skakkebaek et al. 
confirmed the existence of a precursor lesion for TGCTs. Historically, the terms carcinoma in 
situ and testicular intraepithelial neoplasia have been used to describe this lesion, but they 
are no longer preferred because these lesions do not possess epithelial features (Emerson & 
Ulbright, 2010). The preferred term used in recent literature, including this review, is 
intratubular germ cell neoplasia, unclassified (ITGCN). 
ITCGN plays an important role in the development of TGCTs. Since the seminal work by 
Skakkebaek, it has been generally accepted that most TGCTs arise from ITGCN, with the 
notable exception of pediatric germ cell tumors (yolk sac, mature teratoma) and the rare 
spermatocytic seminomas. Subsequent work by von der Maase et al. demonstrated that 
patients with ITGCN will ultimately progress to invasive cancer if left untreated(von der 
Maase et al., 1986). This malignant transformation has led researchers to focus on early 
detection and treatment in order to improve the outcomes in testicular cancer. Advances in 
molecular biology have helped us gain insight into the mechanisms involved in the 
transformation of ITGCN to TGCTs. In this chapter, we will focus on the pathogenesis, risk 
factors, diagnosis and treatment regimens utilized in the management of ITGCN and 
bilateral TGCTs. 
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2. Pathogenesis 
A close association between seminoma and non-seminoma was described long before the 
discovery of ITGCN (Akhtar & Sidiki, 1979; Mark & Hedinger, 1965). Numerous studies 
have since demonstrated that both histologies can often co-exist in the same tumor and 
share similar risk factors, hinting toward a common etiopathogenesis (Bray et al., 2006). The 
likelihood of common origin has also been supported by epidemiological studies. When 
analyzing the testicular cancer incidence between 1973 and 2002, Chia and colleagues found 
the incidence trends of seminoma and non-seminoma were similar to each other suggesting 
common risk factors (Chia et al., 2010). In contrast, these trends were not observed in those 
with pediatric testicular cancer, indicating different inciting factors are involved in this 
population (Lacerda et al., 2009). Histologic studies on orchiectomy specimens taken from 
patients with TGCTs also confirmed the high incidence of a common precursor lesion 
associated with both seminoma and non-seminoma. Following his initial description of 
ITGCN in 1972, Skakkebaek identified ITGCN in 77% of orchiectomy specimens taken from 
patients with seminoma, embryonal carcinoma or terato-carcinoma (Skakkebaek, 1975). 
ITGCN has also been found in as many as 98% of orchiectomy specimens containing both 
seminoma and non-seminoma (Jacobsen et al., 1981). Interestingly, while the majority of 
patients with ITGCN undoubtedly progress to TGCTs, those without evidence of ITGCN 
tend not to develop invasive testicular tumors (von der Maase et al., 1986). This finding 
lends support to the concept that ITGCN serves as the initial gateway to TGCTs.  
A strong connection between ITGCN and TGCTs can be realized through two large autopsies 
studies from Europe, which demonstrated similar prevalence of ITGCN to lifetime risk of 
TGCTs (Giwercman et al., 1991a; Linke et al., 2005). Subsequent studies on infertile men with 
untreated ITGCN found that many will progress to invasive tumors, with risk approaching 
70% at 7 years (von der Maase et al., 1986). There is strong evidence suggesting that ITGCN is 
present years prior to development of overt cancer. Muller and colleagues followed a 10 year-
old cryptorchid boy with repeated testicular biopsies, which showed ITGCN at age 13 and 
eventually invasive malignant growth at age 21 (Muller et al., 1984; Skakkebaek et al., 1987). 
This idea was further supported by the morphological similarity between ITGCN and human 
fetal gonocytes observed by Holstein and Korner in 1974 (Holstein & Korner, 1974). Through 
immunohistochemical and DNA studies, Jorgense and colleagues were able to support their 
hypothesis that ITGCN cells are of prenatal origin and may be a consequence of malignant 
transformation of fetal germ cells in utero (Jorgensen et al., 1993).  
Histologic and molecular studies have provided strong evidence supporting the close 
association between ITGCN and TGCTs. Due to its high serum concentration in seminoma 
patients, placental-like alkaline phosphatase (PLAP), a molecule of unknown biological 
function, was one of the first tumor markers studied for testicular cancer (Jacobsen & 
Norgaard-Pedersen, 1984). Through immunohistochemical experiments, PLAP was found to 
be highly expressed in seminomas, embryonal carcinomas, and ITGCN(Manivel et al., 1987). 
In contrast, expression of PLAP was not observed in normal testicular tissues (Manivel et al., 
1987). As a result of recent advances in molecular pathology, numerous markers specific for 
ITCGN and TGCTs have been discovered. These markers include M2A (Giwercman et al., 
1988a), 49-3F (Giwercman et al., 1990b), TRA-1-60 (Giwercman et al., 1993a), NANOG (Hart 
et al., 2005; Hoei-Hansen et al., 2005a), c-kit (Rajpert-De Meyts & Skakkebaek, 1994), AP-2y 
(Hoei-Hansen et al., 2004b), and OCT 3/4 (de Jong et al., 2005; Jones et al., 2006). Detailed 
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discussion of these markers is beyond the scope of this chapter, but some of them deserve 
further mention here. c-kit is a cell membrane tyrosine kinase receptor responsible for 
migration and survival of primordial germ cells. Its expression is seen in both ITGCN and 
seminoma. Mutations in the c-kit gene are frequently encountered in patients with bilateral 
germ cell tumors but rare in those with unilateral disease (Rajpert-De Meyts, 2006). This 
finding suggests that mutations had occurred prior to migration of primordial germ cells 
early in life and patients with c-kit mutations are prone to develop bilateral germ cell 
tumors. Recently, OCT3/4 has become one of the most widely used germ cell tumor 
markers due to its high specificity and sensitivity for seminoma, embryonal carcinoma and 
ITGCN (Jones et al., 2006). OCT3/4 has been praised as a possible screening tool for patients 
at risk for the development of TGCTs (Cheng et al., 2007; Jones et al., 2006).  
The exact mechanisms involved in the transformation of ITGCN to overt TGCTs are not well 
understood, partly due to the lack of good experimental and animal models (Hoei-Hansen 
et al., 2005b). Down regulation of PTEN and p18 expressions as well as induction of cyclin E 
have been implicated in the progression of ITGCN to invasive tumors (Bartkova et al., 2000; 
Di Vizio et al., 2005). Through comparative genomic analysis, Summersgill and colleagues 
were able to show that the gain of chromosome 12p, a consistent finding in TGCTs, is 
associated with survival of ITGCN independent of Sertoli cells leading to malignant 
transformation (Looijenga et al., 2003; Summersgill et al., 2001). While there is strong 
evidence indicating ITGCN is the precursor for all TGCTs, the question still remains: where 
does ITGCN come from? The most widely accepted hypothesis suggests that ITCGN 
originates from fetal gonocytes and the initiation of malignant transformation most likely 
takes place early in fetal development. This hypothesis was initially based on the close 
morphological similarities between ITGCN and fetal gonocytes noted by Skakkebaek as well 
as other investigators (Gondos et al., 1983; Holstein & Korner, 1974). Subsequent studies 
demonstrating similar expression patterns between ITGCN, TGCTs and fetal gonoctyes of 
many immunohistochemical markers lend further support to this hypothesis (Jorgensen et 
al., 1993). Interestingly, expression of these markers is not seen in the adult testis (Jorgensen 
et al., 1993). Recent development of high throughput expression technology has not only 
provided better characterization of gene expressions of ITGCN at the RNA level but also 
helped us gain further insights into the relationship between ITGCN and fetal gonocytes. By 
comparing the mRNA expression of ITGCN to normal testis tissue, Hoei-Hansen et al. was 
the first to focus on the expression pattern of ITGCN and subsequently identified several 
genes that are important to fetal testicular development (Hoei-Hansen et al., 2004a). In 2004, 
Almstrup and colleagues used genome-wide cDNA microarrays to compare genomic 
expression profiles of ITGCN and embryonic stem cells, a precursor to fetal gonocytes, and 
found a remarkable similarity in expression patterns between these two entities, providing 
additional support that ITGCN is of fetal origin (Almstrup et al., 2004). Similar conclusions 
have been reached by other investigators as well. A recent microarray analysis by Sonne et 
al. demonstrated that the expression patterns of ITGCN cells are more similar to those of 
gonocyte than embryonic stem cells, suggesting that ITGCN may simply be an arrested 
gonocyte that persisted in a postnatal testis (Sonne et al., 2009).  
Two mechanisms regarding the development of ITGCN can be proposed based on the 
current discussion. Whether the formation of ITGCN is related to spontaneous regression of 
spermatogonia toward a primordial germ cell state or an abnormal persistence of an 
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arrested gonocyte beyond the neonatal period remains unanswered. Some researchers have 
attempted to address this through epidemiologic studies by specifically examining the 
correlation between cancer incidence and differences in environmental factors during time 
of fetal development and birth. Moller’s work in 1989 demonstrated lower incidence of 
testicular cancer in men born around the time of World War II than expected from the 
overall increasing trend. His observation supports the hypothesis that environmental 
influences early in life, or in utero, may be the determining factor for testicular cancer 
development (Moller, 1989; 1993). Additional evidence supporting this hypothesis can be 
seen in two cohort studies from Denmark, a country known to have one of the highest 
incidences of testicular cancer. By looking at the incidence of testicular cancer according to 
residence at birth within Denmark, Myrup et al was able to show the risk for TGCTs is 
related to county of birth, rather than county of residence at diagnosis (Myrup et al., 2010). 
When evaluating the testicular cancer risk in first- and second–generation immigrants to 
Denmark, it was found that the first-generation immigrants have TGCT risk similar to their 
country of origin, whereas the second generation has a risk similar to the Danish incidence 
(Myrup et al., 2008). Similar results have been produced by investigators from Sweden as 
well (Hemminki & Li, 2002). All of the evidence presented thus far would argue that the fate 
of testicular cancer is determined early in life, and the transformation of a precursor cell to 
ITGCN is initiated during fetal development.  
3. Risk factors 
Since ITGCN is a precursor lesion for TGCTs, the presence of ITGCN is now recognized as a 
risk factor for TGCTs. However, the incidence of ITGCN in healthy men has not been well 
characterized as the diagnosis of ITGCN requires testicular biopsy. As mentioned earlier, 
two landmark pathological studies attempted to address this question. The researchers from 
Denmark analyzed 399 testes from men between age 18 to 50 years old who died 
unexpectedly and found the overall prevalence of ITGCN to be 0.8%, comparable to the 
lifetime risk of TGCTs in the Danish male population (Giwercman et al., 1991a). The autopsy 
study from Germany also demonstrated similar findings (Linke et al., 2005). A number of 
conditions with high prevalence of ITGCN haven been identified and will be discussed here. 
One of the greatest risk factors for developing TGCTs is a personal history of TGCTs. It has 
been shown that patients with a personal history of testicular cancer have a 25-fold 
increased risk of developing TGCTs in the contralateral testis (Dieckmann et al., 1993). 
Studies on men with TGCTs who underwent contralateral testicular biopsy demonstrated 
consistent rates of ITGCN at around 5-7% (Berthelsen et al., 1982; Dieckmann & Loy, 1996; 
von der Maase et al., 1986). Once again, the prevalence of ITGCN in the contralateral testis 
correlates well with the lifetime risk of developing contralateral TGCTs (Grigor & Rorth, 
1993; von der Maase et al., 1986). Additional studies on men with unilateral TGCTs have 
identified a number of risk factors associated with contralateral ITGCN. Several reports 
have demonstrated testicular atrophy as an independent risk factor for contralateral ITCGN, 
with 4.3-fold increased risk of having positive biopsies in this group of patients (Dieckmann 
& Loy, 1996; Harland et al., 1998). Age at presentation is also a concern for contralateral 
ITGCN. One study showed that diagnosis of TGCTs in patients younger than 30 is 
associated with significant increased risk of positive biopsies on the contralateral testes 
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(Harland et al., 1998). While these findings demonstrate testicular atrophy and age of 
presentation are both strong risk factors for ITGCN, it has also been shown that the majority 
of patients with ITGCN do not have these associated risk factors. A large portion of patients 
with ITGCN would be missed if contralateral biopsies were only performed in patients with 
these risk factors. Dieckmann et al. have advocated for performing biopsies in all men with a 
history of testicular cancer (Dieckmann & Skakkebaek, 1999). In addition to atrophy and age 
of presentation, an irregular echogenic pattern of the contralateral testis on ultrasound has 
been shown to be predictive of positive testicular biopsy for ITGCN in 78 men with 
unilateral TGCTs (Lenz et al., 1996). 
A recent study of 22,562 men in the US demonstrated that infertility is a strong risk factor 
for testicular cancer, suggesting that infertility and testicular cancer share a common 
etiology (Walsh et al., 2009). Similar findings were observed in a study of 2739 patients who 
underwent testicular biopsy for infertility (Bettocchi et al., 1994). In this cohort, 16 patients 
had unilateral ITGCN and testicular atrophy, 50% progressed to invasive TGCTs. Previous 
studies have shown that the incidence of ITGCN in infertile men is about 0.4-1.1% (Pryor et 
al., 1983; Skakkebaek, 1978). A recent retrospective review of biopsies from 453 subfertile 
men revealed a 2.2% risk of ITGCN, compared to an estimated risk of 0.45% in an age- and 
birth-matched cohort, suggesting that infertility is a risk factor for ITGCN (Olesen et al., 
2007). In agreement with previous findings, these authors concluded that severe 
oligospermia and atrophic testes are associated risks for ITGCN.  
Patients with cryptorchidism or undescended testes (UDT) are at an increased risk for 
developing testicular cancer. A recent meta-analysis review of 11 studies demonstrated that 
men with UDT are at a 6.3-fold increased risk for TGCTs, compared to 1.7-fold increase in 
the unaffected testes (Akre et al., 2009). Furthermore, there is strong evidence suggesting 
that orchiopexy before puberty has a protective effect against development of testicular 
cancer (Wood & Elder, 2009). While there is convincing evidence linking cryptorchidism to 
testicular cancer, the relationship between UDT and prevalence of ITGCN remains unclear. 
An early biopsy study on 50 men with cryptorchidism demonstrated the prevalence of 
ITGCN in this cohort is around 8% (Krabbe et al., 1979). In contrast, a larger study involving 
300 patients with UDT found the prevalence of ITGCN to be 1.7% (Giwercman et al., 1989). 
Furthermore, previous studies on the prevalence of ITGCN in patients with unilateral 
TCGTs found that history of cryptorchidism is not predictive of ITGCN (Dieckmann & Loy, 
1996; Harland et al., 1993). Unlike cryptorchidism, patients with sexual developmental 
disorders have been shown to have high rates of ITGCN and TGCTs in several small studies 
(Skakkebaek, 1979; Slowikowska-Hilczer et al., 2001).  
Significant controversy surrounds the association between testicular microlithiasis (TM) and 
the subsequent development of ITCGN and TGCTs. In an otherwise healthy population, TM 
is not considered a risk factor for TGCTs. One study involving 63 healthy men with TM 
demonstrated that 98.5% of this cohort remained cancer-free 5 years after the initial 
screening (DeCastro et al., 2008). Furthermore, the incidence of TM in asymptomatic young 
men is reportedly to be 1.5-5.6% (DeCastro et al., 2008; von Eckardstein et al., 2001). On the 
other hand, the association between TM and TGCTs is also well documented, with high 
incidence of TM observed in patients with testicular cancer (Ikinger et al., 1982; Sanli et al., 
2008). Recently, a large meta-analysis attempted to address this issue by looking at the 
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association of TM with TGCT and ITGCN (Tan et al., 2010). The authors found no 
association between TM and increased risk of TCGT in the otherwise healthy males. 
However, in those patients at risk for TGCTs, such as infertility, UDT or history of unilateral 
TGCT, the presence of TM is associated with approximately a 10-fold increased risk for 
concurrent diagnosis of TGCT or ITGCN. These findings are in an agreement with previous 
studies as well. Holm et al. demonstrated the presence of TM in the contralateral testis of 
men with unilateral TGCTs is associated with about a 30-fold increased risk of ITGCN 
(Holm et al., 2003). Furthermore, the incidence of TM in infertile men has been shown to be 
2-20%, which is considerably higher than that of the general population (de Gouveia Brazao 
et al., 2004; von Eckardstein et al., 2001). Others have suggested that bilateral microlithiasis 
and sonographic heterogeneity in subfertile men are associated with increased risk of 
developing ITGCN (de Gouveia Brazao et al., 2004; Elzinga-Tinke et al., 2010), indicating the 
need to follow these patients closely with frequent biopsy or ultrasound. 
4. Diagnosis 
There are no imaging modalities or serum tumor markers to accurately diagnose ITGCN. 
Currently, testicular biopsy is the only reliable method to diagnose ITGCN. The pathologic 
morphology of ITGCN is well-defined and is similar to that of seminoma. The ITGCN cells 
are larger than normal spermatogonia, and possess larger nuclei with prominent nucleoli 
(Gondos & Migliozzi, 1987). The cytoplasm is rich with glycogen and contains the enzyme 
PLAP (Dieckmann et al., 2011; Lauke, 1997). These abnormal cells are located at the 
basement membrane of the seminiferous tubules and the tubules vary from containing 
adjacent normal Sertoli cells and spermatogonia to complete dominance of ITGCN cells 
(Jacobsen et al., 1981). A good biopsy sample should be at least 3 x 3 mm in size and 
contains at least 30-40 tubules on microscopic examination (Holstein & Lauke, 1996). 
Testicular biopsies should be placed in Boulin’s or Stieve’s solution; Formalin fixation 
should be avoided because it can greatly alter the morphology of testicular architecture. 
Immunohistochemical markers are routinely used during histological examination to aid the 
diagnosis of ITGCN. The importance of immunohistochemistry (IHC) was highlighted in a 
recent review of 20 patients with TGCTs and prior negative testicular biopsy (van Casteren 
et al., 2009). Seven cases of ITGCNs and TGCTs were diagnosed by experienced pathologists 
based on morphology alone, but an additional 4 cases were identified with IHC. As 
mentioned earlier, PLAP has traditionally been the most widely used IHC marker to 
identify ITGCN, with sensitivity ranging from 83-98% (Jacobsen & Norgaard-Pedersen, 
1984; Manivel et al., 1987). Several studies recently have demonstrated a superior IHC 
marker for detecting ITGCN, OCT3/4, which has sensitivity and specificity approaching 
100% (Cheng et al., 2007; de Jong et al., 2005; Jones et al., 2006). A pathologic representation 
of ITGCN stained with OCT 3/4 is portrayed in Fig. 1. 
As open testicular biopsy is invasive and has the potential for complications, detection of 
ITGCN by semen analysis has been investigated. The ability to use semen to detect ITGCN is 
based on the original work by Giwercman when he observed the exfoliation of ITGCN cells 
from the seminiferous tubules into the seminal fluid in men with TGCTs (Giwercman et al., 
1988b). However, the detection rate of ITGCN cells in semen is far inferior to open surgical 
biopsy (Brackenbury et al., 1993). Subsequent studies have attempted to increase the sensitivity 
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of semen analysis for CIS by combining DNA flow cytometry and in situ hybridization 
without great success (Giwercman et al., 1990a). Recently, investigators from Denmark sought 
to improve the detection rate on semen analysis by developing a sophisticated model 
involving immunocytochemical staining of ejaculates from infertile men (Almstrup et al., 
2011). This approach demonstrated an overall sensitivity and specificity of 0.67 and 0.98, 
respectively, when compared to open surgical biopsy. These non-invasive methods for 
detection of ITGCN are promising but their clinical feasibility remains to be seen.  
Fig. 1. Pathologic features of ITGCN. A – H&E stained section demonstrates typical features 
of ITGCN: cells with large nuclei and prominent nucleoli located along the basement 
membrane of the seminiferous tubules. B – Immunohistochemical staining of ITGCN cells 
with OCT 4 demonstrating a nuclear staining pattern (Jones et al., 2004). (Courtesy of Liang 
Cheng, MD, Indiana University School of Medicine, Indianapolis, IN) 
A
B
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4.1 Testicular biopsy 
The distribution of ITGCN cells within a testis has been a subject of contention and is 
directly linked to the accuracy of testicular biopsy. Based on their biopsy simulation 
experiments, Berthelsen and Skakkebaek hypothesized that ITGCN cells are homogenously 
dispersed throughout the testis and demonstrated that a 3-mm biopsy is a sufficient 
representation of the entire testis (Berthelsen & Skakkebaek, 1981). Early studies had 
supported this theory by demonstrating the low false-negative biopsy rates associated with 
the single biopsy technique. In a study involving 1859 negative testicular biopsies in the 
contralateral testes of patients with TGCTs, only 5 patients (0.3%) developed TGCTs 
(Dieckmann & Loy, 2003). The same authors re-examined their data recently and, again, 
showed the overall proportion of false-negative biopsies for detecting ITCGN is about 0.5% 
(Dieckmann et al., 2005). Some investigators have sought to improve the sensitivity of 
testicular biopsy by performing multiple biopsies on the same testis. In a series of 2318 men 
with TGCTs who underwent double-biopsy of the contralateral testes, the discordance rate 
was 31% with an extra yield of 18% in diagnosis (Dieckmann et al., 2007). The high 
discordance rate in this study suggests that the distribution of ITGCN within a testis is 
heterogeneous rather than homogenous. This finding is further supported by several 
ITGCN mapping studies that demonstrated a focal pattern of ITGCN adjacent to TGCTs 
(Loy et al., 1990; Prym & Lauke, 1994). The heterogeneous distribution of ITGCN would also 
provide an explanation for the development of TGCTs despite prior negative biopsies. 
Based on this assumption, Dieckmann and colleagues were able to increase the diagnostic 
yield of ITGCN by performing a second biopsy at a different site (Dieckmann et al., 2007). 
This is in accord with a study involving triple biopsies of the contralateral testis, which 
demonstrated an 8% increase in detection of ITGCN (Kliesch et al., 2003). However, this 
approach may result in a higher complication rate especially in the setting of a solitary testis. 
Furthermore, it remains to be seen whether the benefit of multiple biopsies outweighs its 
risks. Even with this approach subsequent TGCTs in patients with prior negative double 
biopsy have been reported (Souchon et al., 2006). 
Complications associated with testicular biopsy remain a major concern and have prevented 
many clinicians from adopting this approach as routine screening protocol. Current 
literature suggests the overall rates of complication secondary to testicular biopsy range 
from 3 – 20% (Dieckmann et al., 2005; Heidenreich & Moul, 2002). In a prospective study of 
1874 men with testicular cancer who underwent contralateral testicular biopsy, the overall 
complication rate of 2.8% was noted with 0.64% requiring repeat surgery and one testis 
(0.05%) was lost (Dieckmann et al., 2005). In the same series, a subset of patients were 
followed with serial scrotal sonographic and magnetic resonance imaging, which 
demonstrated early post-operative changes, such as hematoma or edema, in 33% - 45% of 
patients. However, these changes spontaneously resolved in 96% of patients 18 months after 
the initial biopsy, suggesting testicular biopsy is a procedure with low-surgical risks. 
Despite resolution of post-surgical changes on imaging, the impact of surgical biopsy on 
testicular endocrine function remains to be addressed in this cohort of patients. Studies on 
infertile men have reported decrease in serum testosterone level following testicular biopsy, 
with some developing hypogonadism (Manning et al., 1998); however, these cases were 
done with significantly more biopsies per testis and the effect was self-limiting. 
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The question of which group of patients should undergo testicular biopsy has been a subject 
of controversy, with varying responses to the same data. The fundamental argument for 
routine testicular biopsy is early diagnosis of TGCTs at the precursor stages. The most 
common scenario in which testicular biopsy is performed to detect ITGCN is in the 
contralateral testes of patients with a history of unilateral TGCTs. Surgical biopsy of the 
contralateral testis at the time of initial orchiectomy is routinely done in Denmark and 
Germany, two counties with the world’s highest incidences of TGCTs (Dieckmann et al., 
2011). Others have advocated for biopsy only in those with TGCTs and risk factors for 
contralateral ITGCN, such as testicular atrophy, history of cryptorchidism, age less than 30 
years, infertility and TM (Dieckmann et al., 2011; Heidenreich, 2009). As demonstrated 
earlier, those who routinely perform testicular biopsy have consistently demonstrated a 5-
7% incidence rate of ITGCN in the contralateral testis, and 70% of them progress to TGCTs 
at 7 years (Dieckmann & Loy, 1996; von der Maase et al., 1986). Early identification of these 
high risk patients allows for organ-sparing therapy, which may potentially preserve 
endocrine function in contrast to a second orchiectomy (Dieckmann & Skakkebaek, 1999). 
Additionally, diagnostic delay in patients with TGCTs has been shown to significantly 
impact survival, which highlights the importance of early diagnosis (Huyghe et al., 2007). 
Since the rate of false-negative biopsy is exceedingly low (0.5%), a negative testicular biopsy 
translates into a very low probability of having a second TGCTs. This may dictate a less 
intensive surveillance protocol as well as alleviate psychological distress associated with 
diagnosis of cancer in high-risk patients. 
The arguments against the practice of routine testicular biopsy in these patients are also 
convincing. In contrast to the standard of care in Denmark and Germany, physicians in the 
US are less likely to perform routine testicular biopsy in patients with TGCTs partly due to a 
lower incidence of contralateral cancer (Coogan et al., 1998; Fossa et al., 2005). In a large 
series of nearly 30,000 patients with unilateral TGCT, the investigators demonstrated an 
overall risk of developing contralateral TGCTs is 1.9% in the US (Fossa et al., 2005), which is 
considerably lower than the 5-7% reported by the European studies. Furthermore, these 
authors demonstrated patients with contralateral TGCTs had excellent long-term prognosis, 
with an overall survival rate of 93% at 10 years after initial diagnosis, providing support for 
continuing the US approach of not subjecting contralateral testis to biopsy. Others have also 
demonstrated good clinical outcomes in patients with bilateral TGCTs who are treated 
appropriately for histology and stage (Holzbeierlein et al., 2003). Other arguments favoring 
the omission of routine biopsy include the added cost associated with surgery as well as 
exposing the majority of patients unnecessarily to the surgical risks in order to benefit a few 
individuals. As discussed earlier, testicular biopsy to screen for ITGCN is not a perfect 
technique; many cases of contralateral tumor occurrence have been reported in patients with 
negative prior biopsies, even with the double biopsy approach (Souchon et al., 2006). 
Finally, the most widely accepted organ-sparing therapy for ITGCN is radiotherapy, which 
has been shown to destroy both endocrine and exocrine function of a testis, with one study 
demonstrating high incidence of hypogonadisim after radiation requiring androgen 
supplementation (Petersen et al., 2002). Until methods of diagnosis are improved or a 
survival benefit is demonstrated with early diagnosis of ITGCN, treatment decisions need to 
be made based on data presented and individualized for patient risk factors and wishes.  
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5. Treatment 
The primary goal of treating ITCGN is to prevent its malignant transformation to TGCT. 
Presently, there are four options to managing ITGCN: chemotherapy, radiation, orchiectomy 
and surveillance. With the exception of surveillance, the remaining three treatment 
modalities put patients at significant risk for infertility, hypogonadism, or both. The 
decision to proceed with a certain treatment modality has to be individualized based upon 
specific risk factors as well as patient wishes.  
5.1 Chemotherapy 
It was initially thought that chemotherapy could completely eradicate ITGCN and prevent 
development of contralateral TGCT. This idea was based on the observation that patients 
receiving chemotherapy had no progression of disease and had complete resolution of 
ITGCN on repeat biopsy, whereas 7 out of 18 patients without chemotherapy progressed to 
overt cancer (von der Maase et al., 1985). However, three years after their initial publication, 
the same investigators reported that one patient in the chemotherapy group had recurrence 
of ITGCN on repeat biopsy (von der Maase et al., 1988). Numerous reports since then 
demonstrated chemotherapy to be an ineffective regimen for treating ITGCN. One series 
estimated the risk of recurrent ITGCN 5 and 10 years after termination of chemotherapy to 
be 21% and 42%, respectively (Christensen et al., 1998). Histological analysis on orchiectomy 
specimens obtained from patients who had chemotherapy demonstrated persistence of 
ITGCN in 35% of patients (Bottomley et al., 1990). Possible explanations behind this 
phenomenon include the presence of blood-testis barrier or insensitivity of ITGCN cells to 
chemotherapy (Mortensen et al., 2011; Ploen & Setchell, 1992). In a recent study of 11 
patients with unilateral TGCTs and biopsy-proven ITGCN in the contralateral testis treated 
with chemotherapy, 64% of them had ITGCN on repeat biopsy, providing support that 
chemotherapy is ineffective at eradicating ITGCN (Kleinschmidt et al., 2009).  
5.2 Radical orchiectomy  
Unlike chemotherapy, orchiectomy is the most definitive treatment with the highest success 
rate and is the main treatment approach for three patient populations: those with unilateral 
ITGCN and contralateral normal testis; those with an atrophic testis; and those with 
infertility and unilateral ITGCN (Dieckmann & Skakkebaek, 1999; Mortensen et al., 2011). In 
patients with a solitary testis, orchiectomy in this population needs to be weighed against 
the risk of infertility and permanent dependence on exogenous testosterone replacement.  
5.3 Radiation 
Local radiation has become the preferred treatment modality for ITGCN because it is organ-
sparing and highly effective at eradicating ITGCN cells. The rationale behind employing 
radiotherapy is based on the finding that radiation has the propensity to destroy ITGCN 
and germ cells while preserving Leydig cell function (von der Maase et al., 1985). Therefore, 
it has the potential of preserving testicular endocrine function while eliminating neoplastic 
cells. Presently, three major concerns have been raised regarding radiotherapy in the 
treatment of ITGCN. First, the radiation dose for optimal oncologic control has not been 
determined (Mortensen et al., 2011). The current recommended dose according to guidelines 
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put forth by the European Association of Urology is 20 Gy delivered over 2 weeks (Albers et 
al., 2005). This dose has previously been shown to be very effective at eradicating ITGCN 
cells, with one series demonstrating complete resolution of ITGCN on repeat biopsy at a 
follow-up of 2 years (Giwercman et al., 1991b). Another group from Denmark studied the 
effect of radiotherapy in doses 14 to 20 Gy on eradication of ITGCN testes, and 
demonstrated that all patients treated with radiation dose level 16 to 20 Gy had complete 
resolution of ITGCN while one patient treated at dose level 14 Gy had a recurrence at a 
follow up of 5 years (Petersen et al., 2002). However, recurrences of ITGCN have been 
reported at all dose levels up to 20 Gy (Classen et al., 2003; Dieckmann et al., 2002; Dotsch et 
al., 2000; Petersen et al., 2002). Currently, there is no consensus on the optimal radiation 
dose to achieve cancer control, but most would agree that a dose level of 16 to 20 Gy is 
effective. The second concern is in regards to the effect of radiation on testicular exocrine 
function. Local radiation to the testis will result in the destruction of both ITGCN and germ 
cells, subsequently rendering these patients infertile. Proponents of local radiation to 
solitary testes argue that patients with ITGCN already have severely impaired 
spermatogensis prior to therapy (Giwercman et al., 1993b; Petersen et al., 1999); therefore, 
radiation should not have significant impact on the development of infertility. However, 
improvement in spermatogenesis has been noted following removal of unilateral TGCTs 
(Carroll et al., 1987) and cases of successful conception in patients with ITGCN have been 
reported (Heidenreich et al., 1997). Therefore, it is important to consider surveillance or 
postponing radiation to allow for paternity in patients with ITGCN in the solitary testis. The 
third concern is the impairment of testicular endocrine function by local radiation. 
According to one series of patients with ITGCN in solitary testis, serum luteinizing hormone 
remained significantly elevated post radiation and 25% of patients require permanent 
androgen supplementation (Giwercman et al., 1991b). This finding led to several 
investigations on dose reduction, with one study demonstrating the impairment on 
endocrine function was independent of radiation dose and the need for androgen 
substitutions was similar at all dose levels (Petersen et al., 2002). Others found less toxic 
effect on testicular Leydig cell function with lower radiation doses at 13 and 16 Gy (Bang et 
al., 2009; Sedlmayer et al., 2001). All patients undergoing radiation therapy need to have 
their hormone function checked on a regular basis in order to identify those where androgen 
supplementation is needed.  
5.4 Active surveillance  
For select patients, active surveillance may be the treatment of choice. This is particularly 
true for those with ITGCN in the solitary testis who desire to preserve fertility and hormone 
function. Surveillance can be justified in these patients but they must be counseled on the 
risk of developing invasive cancer and the need for subsequent orchiectomy. Furthermore, 
these patients need to be compliant with regular follow-up and, more importantly, frequent 
testicular self-examination. If preserving fertility is the goal, semen analysis should be obtained 
and cryopreservation of viable sperm should be considered before treatment is initiated 
(Dieckmann & Skakkebaek, 1999). For those patients who progress to TGCTs, partial 
orchiectomy may be an acceptable treatment if the tumor is organ-confined and less than 2cm 
in size (Heidenreich et al., 2001). Consistent with the discussion above, as most patients in this 
series (82%) had associated ITGCN, most were treated with adjuvant radiation and relapses 
were only observed in those who did not receive radiation treatment. Partial orchiectomy is 
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still in the investigational phase, and patients should be counseled on the risk of disease 
progression and the need for radical orchiectomy if a tumor recurs in that testis.  
6. Bilateral testicular cancer 
While the risk of developing contralateral testicular cancer is high in patients with unilateral 
TGCTs, there is no clear consensus on how these patients should be managed. Perhaps, we 
can gain further insight into this issue by looking at the outcome data of patients with 
bilateral testicular cancer. The reported incidence of bilateral TGCTs in the US and Europe is 
estimated to be 1- 4% (Bokemeyer et al., 1993; Che et al., 2002; Coogan et al., 1998; Fossa et 
al., 2005; Hentrich et al., 2005; Holzbeierlein et al., 2003; Pamenter et al., 2003). In these 
contemporary series, metachronous presentations were the majority (62-88%) and the 
median interval between first and second testicular tumor was 50 – 76 months. Recent 
studies demonstrated that the clinical outcomes of metachronous TGCTs were excellent 
(Albers et al., 1999; Che et al., 2002; Coogan et al., 1998; Fossa et al., 2005), with the majority 
of patients presenting with clinical stage 1 disease (44 – 90%). Furthermore, the 10-year 
survival rate following a diagnosis of metachronous bilateral testis cancer was 93%, which is 
comparable to patients diagnosed with unilateral TGCTs (95%)(Fossa et al., 2005). Single 
institution studies from Indiana, M.D. Anderson, and Memorial-Sloan-Kettering also 
demonstrated excellent prognosis in these patients, with most reporting very low mortality 
from TGCTs (Che et al., 2002; Coogan et al., 1998; Holzbeierlein et al., 2003). Despite such a 
high cure rate, most patients in these studies did not undergo contralateral testicular biopsy. 
This finding certainly questions the value of contralateral testicular biopsy to screen for 
ITGCN. Based on the excellent outcomes observed in bilateral TGCTs, active surveillance, 
perhaps, should play an important role in the management of patients with contralateral 
ITGCN.  
7. Conclusions 
The incidence of testicular cancer is increasing worldwide and it has nearly doubled in the 
last 40 years. This increasing incidence has led researchers to focus on the pathogenesis of 
ITGCN, which has now been established as the precursor lesion for most TGCTs. Several 
theories have been proposed regarding the origin of ITGCN, and recent studies seem to 
suggest it is abnormal persistence of an arrested gonocyte beyond the neonatal period. The 
fate of testicular cancer is determined early in life, and the transformation of a precursor cell 
to ITGCN cell is initiated in utero. Incidence trends of testicular cancer can potentially be 
altered by continued exploration of the contributing factors in the pre- and peri-natal period. 
The diagnosis and management of patients with ITGCN remain a challenging problem for 
clinicians, and indications for testicular biopsy to detect ITGCN are controversial. The 
decision to proceed with a certain treatment modality should be individualized and needs to 
be based on specific risk factors as well as patient wishes. Radical orchiectomy and radiation 
therapy are the only two effective means of preventing subsequent TGCTs in a testis with 
ITGCN. Both treatment options can result in infertility as well as hormone dysfunction. 
Metachronous bilateral TGCTs occur infrequently but the clinical outcomes are excellent, 
suggesting that the role of active surveillance needs to be emphasized in the management of 
contralateral ITGCN in a solitary testis.  
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